Gilead-backed study warns IRA price negotiations could hit R&D harder than expected

How hard will the Inflation Reduction Act (IRA) hit pharma R&D? Harder than the government expected, according to work by the University of Chicago that found lower R&D spending could result in 79 fewer new small-molecule drugs over the next 20 years.